CytoDyn appoints Ryan Dunlap as director, effective Aug 25, 2022

CytoDyn Inc.

Ryan Dunlap appointed as director, filling vacancy from Nader Pourhassan's Jan 2022 resignation.
Expected to join the Audit Committee; Dunlap has over 25 years of finance and operations leadership.
Currently CFO at Gurobi Optimization; prior CFO at a publicly traded biotech/pharma sales company.
Compensation consistent with non-employee director policies; includes cash retainers and stock options.
No family relationships or transactions requiring disclosure under Item 404(a) of Regulation S-K.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Ryan Dunlap

director

CYDY · CytoDyn Inc.

Effective: 2022-08-25
Filed: August 30, 2022, 7:59 PM ET

On August 24, 2022, the Board of Directors (the “Board”) of CytoDyn Inc. (the “Company”) approved the appointment of Ryan Dunlap (“Mr. Dunlap”), as a director of the Company, effective August 25, 2022.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Ryan Dunlap was appointed as director at CytoDyn Inc..

Action: appointed
Role: director

Exact text from the filing

On August 24, 2022, the Board of Directors (the “Board”) of CytoDyn Inc. (the “Company”) approved the appointment of Ryan Dunlap (“Mr. Dunlap”), as a director of the Company, effective August 25, 2022.

View on SEC.gov

CytoDyn Inc. filing history →

Source: SEC EDGAR

accession 0001558370-22-014068

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.